Daiichi Sankyo
Daiichi Sankyo Inc.
2 Hilton Court
Parsippany, NJ 07054
Phone: (973) 944-2600Website: https://dsi.com/homePatient Assistance Program: dsi.com/patient-assistance-programs
Latest news
- FDA Approves Vanflyta (quizartinib) for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
20 July 2023 - Injectafer Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure
5 June 2023 - Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA
21 April 2023 - Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
24 October 2022 - Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
11 June 2022 - Injectafer (ferric carboxymaltose injection) Receives FDA Approval for the Treatment of Pediatric Patients with Iron Deficiency Anemia
16 December 2021 - Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML
18 November 2021 - Injectafer (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia
6 May 2021 - FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumors (TGCT) in Adults
2 August 2019 - Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
21 June 2019
Drugs Associated with Daiichi Sankyo Inc.
Daiichi Sankyo Inc. manufactures, markets and/or distributes more than 6 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Datroway
Generic name: datopotamab deruxtecan Drug class: miscellaneous antineoplastics |
||
|
Enhertu
Generic name: fam-trastuzumab deruxtecan Drug class: HER2 inhibitors |
24 reviews | 8.2 / 10 |
|
Injectafer
Generic name: ferric carboxymaltose Drug class: iron products |
7 reviews | 7.4 / 10 |
|
Savaysa
Generic name: edoxaban Drug class: factor Xa inhibitors |
2 reviews | 1.0 / 10 |
|
Turalio
Generic name: pexidartinib Drug class: multikinase inhibitors |
||
|
Vanflyta
Generic name: quizartinib Drug class: multikinase inhibitors |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||